Correlation of PDK1 expression with clinicopathologic features and prognosis of hepatocellular carcinoma.
OBJECTIVE
To explore the clinical significance of 3-phosphoinositide-dependent protein kinase-1 (PDK1) expression in hepatocellular carcinoma (HCC) and its association with clinicopathologic features and prognosis in HCC patients.


METHODS
A total of 128 HCC patients who received radical resection were enrolled from Wenling Maternal and Child Health Care Hospital between May 2005 and December 2008, and tumor and adjacent tissue samples were collected. Expression of PDK1 was detected by immunohistochemistry method. Correlation of PDK1 expression with clinicopathological features and prognosis was determined by Spearman's correlation analysis. Impact of expression of PDK1 on overall survival and recurrence was determined by Kaplan-Meier analysis.


RESULTS
Immunohistochemistry results showed that PDK1 expression in HCC tissues was significantly higher than that in the corresponding adjacent cancer tissues. Univariate analysis showed that PDK1 messenger RNA expression can predict time to recurrence with diagnostic significance (P=0.001). Univariate analysis showed that alpha-fetoprotein level, tumor number, tumor encapsulation, microvascular invasion, and tumor-node-metastasis stage were also unfavorable prognostic variables for recurrence (P<0.05). Kaplan-Meier analysis showed that overexpression of PDK1 correlates with significantly shorter postoperative overall survival and higher recurrence rates (hazard ratio =2.68; 95% confidence interval: 2.46-4.42, P=0.001) in HCC patients after curative resection.


CONCLUSIONS
Our study indicated that PDK1 may serve as a candidate pro-oncogene and a potential prognostic biomarker for HCC.
Department of Laboratory Medicine, Wenling Maternal and Child Health Care Hospital, Wenling, Zhejiang Province, People's Republic of China.
Junrong
J
Wang
Department of Laboratory Medicine, Wenling Maternal and Child Health Care Hospital, Wenling, Zhejiang Province, People's Republic of China.
Fenqin
F
Liu
Department of Laboratory Medicine, Wenling Maternal and Child Health Care Hospital, Wenling, Zhejiang Province, People's Republic of China.
Peiran
P
Ao
Department of Laboratory Medicine, Wenling Maternal and Child Health Care Hospital, Wenling, Zhejiang Province, People's Republic of China.
Xianneng
X
Li
Department of Laboratory Medicine, Wenling Maternal and Child Health Care Hospital, Wenling, Zhejiang Province, People's Republic of China.
Haixiao
H
Zheng
Department of Laboratory Medicine, Wenling Maternal and Child Health Care Hospital, Wenling, Zhejiang Province, People's Republic of China.
Di
D
Wu
Department of Laboratory Medicine, Wenling Maternal and Child Health Care Hospital, Wenling, Zhejiang Province, People's Republic of China.
Nina
N
Zhang
Department of Laboratory Medicine, Wenling Maternal and Child Health Care Hospital, Wenling, Zhejiang Province, People's Republic of China.
Junping
J
She
Department of Laboratory Medicine, Wenling Maternal and Child Health Care Hospital, Wenling, Zhejiang Province, People's Republic of China.
Junhui
J
Yuan
Department of Laboratory Medicine, Wenling Maternal and Child Health Care Hospital, Wenling, Zhejiang Province, People's Republic of China.
Xiuying
X
Wu
3-phosphoinositide-dependent protein kinase-1; AFP; HCC; PDK1; TNM stage; alpha-fetoprotein; hepatocellular carcinoma; microvascular invasion; prognosis; tumor–node–metastasis
Anticancer Res. 2015 Nov;35(11):6329-34
26504072
Mol Carcinog. 2016 Nov;55(11):1613-1626
26455908
Pancreas. 2014 Oct;43(7):1093-100
25036909
Tumour Biol. 2016 Feb;37(2):2333-9
26373731
Hum Pathol. 2009 Oct;40(10):1434-40
19427017
Blood. 2004 Oct 15;104(8):2345-52
15187024
Cancer Treat Rev. 2016 Apr;45:77-86
26995632
Nat Rev Gastroenterol Hepatol. 2014 Jan;11(1):45-54
23938452
J Clin Gastroenterol. 2013 Jul;47 Suppl:S2-6
23632345
Oncology. 2015;89(6):351-9
26439504
Curr Med Chem. 2011;18(18):2763-9
21568903
Cell Metab. 2015 Oct 6;22(4):577-89
26365179
J Hepatol. 2003 Dec;39(6):1076-84
14642630
J Hepatol. 2015 May;62(5):1187-95
25681552
Oncotarget. 2015 Oct 6;6(30):29076-86
26318166
Biochem Soc Trans. 2014 Oct;42(5):1435-40
25233428
Cell Physiol Biochem. 2013;32(5):1497-508
24335175
Oncology. 2010 Jul;78 Suppl 1:180-8
20616602
Biochim Biophys Acta. 2015 Dec;1856(2):178-88
26238471
Oncogene. 2016 Jun 23;35(25):3314-23
26455327